Clinical trial · Interventional
68-Ga-FAPI PET Imaging in Malignancy
68Ga-FAPI PET Imaging in Malignancy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): no patients enrolled into study
Summary
Brief summary (as posted)
This feasibility trial studies the use of gallium-68 (68Ga)-FAPI as the imaging agent for positron emission tomography (PET)/computed tomography (CT), collectively PET/CT, in patients with various cancers. PET uses a radioactive substance called 68Ga-FAPI, which attaches to cancer activated fibroblasts. The PET scanner takes pictures that capture where the radioactive drug is "lighting up" and attaching to tumor cells, which may help doctors recognize differences between tumor and healthy tissue. CT uses X-rays to make a picture of areas inside the body. Using 68Ga-FAPI in diagnostic procedures, such as PET/CT, may allow doctors to identify smaller tumors than standard imaging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-FAPI | Drug | — | UNRESOLVED |
| Computed Tomography (CT) scan | Procedure | — | UNRESOLVED |
| Positron Emission Tomography (PET) scan | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga-FAPI PET/CT
- description
- Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.
- interventionNames
- Drug: 68Ga-FAPI
- Procedure: Computed Tomography (CT) scan
- Procedure: Positron Emission Tomography (PET) scan
Primary outcomes (1)
- measure
- Feasibility of 68Ga-FAPI PET
- timeFrame
- 24 months
- description
- Feasibility of 68Ga-FAPI PET/CT imaging will be done to assess patients with malignancy. Feasibility will be measured using Likert scale (1-non diagnostic; 5-excellent; anything 3 or more is diagnostic). The study will be feasible if \> 50% of scans will have a score of 3 or more
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with current malignancy confirmed via pathology or imaging * Patient must be \> 18 years old * Patient must be willing and able to provide written informed consent for the trial * Patient of reproductive potential will have a pregnancy test Exclusion Criteria: * Pregnant or breastfeeding
References
Publications (0)
Data not yet available